SCHEDULE 13D: Activist Investor Demands Liquidation or Sale of AN2 Therapeutics After Lead Drug Failure

BML Investment Partners, holding 19.1% of AN2 Therapeutics, has filed a Schedule 13D advocating for an orderly winddown, liquidation, and capital return to shareholders following the Phase 3 failure of the company's lead drug, EBO-301.

Summary

• BML Investment Partners, L.P. and BML Capital Management, LLC (collectively BML) beneficially own 5,749,432 shares of AN2 Therapeutics, Inc. Common Stock, representing 19.1% of the class.
• The shares were acquired for investment purposes using $6,143,308 of working capital.
• BML believes an orderly winddown, liquidation, and capital return, or a sale of the company, is in the best interests of shareholders.
• This stance follows the Phase 3 failure of EBO-301, AN2 Therapeutics' lead drug and only compound currently in the clinic.
• BML estimates shareholders could receive $1.70 or more per share from a swift liquidation, excluding potential value from preclinical programs.
• BML plans to withhold its vote for all three directors at the upcoming annual meeting of stockholders as a referendum on shareholder preferences regarding the company's future path.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the failure of the lead drug, the company's only clinical asset, and the strong call for liquidation by a major shareholder, indicating a lack of confidence in the current strategy and future prospects.

Positives

• A significant shareholder (BML Investment Partners) is actively advocating for a strategy (liquidation/sale) that could potentially return cash to shareholders, estimated at $1.70 or more per share.
• The filing clearly outlines a path for shareholders to express their preference through withholding votes for directors at the upcoming annual meeting.

Negatives

• AN2 Therapeutics' lead drug and only clinical compound, EBO-301, failed its Phase 3 trial.
• The company currently has nothing in the clinic and no meaningful milestones expected in the next two years.
• BML views pursuing preclinical assets into the clinic as "by far the riskiest and least likely path to success" and "very unwise."
• The shareholder base has significantly turned over since early 2024 due to poor efficacy signs in Phase 2 trials.
• BML labels the company as potentially becoming "another zombie biotech" if it does not pursue liquidation or sale.

Risks

• Risk of not returning cash to shareholders if the company pursues preclinical assets, leading to a "very unwise path."
• Risk of becoming a "zombie biotech" with no clinical programs and no meaningful milestones for two years.
• Risk of low odds of success for preclinical programs if taken into the clinic.
• Risk of continued value erosion if the company does not liquidate or sell.

Future Outlook

BML Investment Partners believes that the most prudent future path for AN2 Therapeutics is an orderly winddown, liquidation, and return of cash to shareholders, or a sale of the company, given the Phase 3 failure of its lead drug. They view the alternative of advancing preclinical assets as highly risky with low odds of success and no meaningful milestones for the next two years.

Management Comments

• "Given last weeks unfortunate phase 3 failure of EBO-301, the companys lead drug and only compound currently in the clinic, BML believes strongly that the best course of action from here is a sale of the company or an orderly winddown of operations and return of cash to shareholders."
• "If the Board acts swiftly in this regard, BML believes we could receive $1.70 or more per share before assigning value, if any, to a potential CVR for the companys pre-clinical programs."
• "Trying to create value by taking the companys preclinical assets into the clinic by itself is by far the riskiest and least likely path to success."
• "With nothing in the clinic and no meaningful milestones in the next 2 years, BML believes that the odds of success here are very low, and therefore a very unwise path for the company."
• "BML plans to withhold its vote for all three directors at the upcoming annual meeting of stockholders and suggests other owners who prefer a timely cash return do the same. This vote will provide a referendum as to shareholder preferences on the path forward."
• "The AN2 Board has an easy choice here. It can pursue a strategy that quickly returns cash to shareholders or become another zombie biotech."

Industry Context

The situation highlights the inherent high-risk nature of drug development, particularly in the biotech sector where a single clinical trial failure, especially for a lead and only clinical-stage asset, can drastically alter a company's prospects. It also reflects a common scenario where early-stage biotech companies, after clinical setbacks, face pressure from investors to liquidate and return capital rather than pursue long-shot preclinical programs, often becoming "negative enterprise value" entities.

Comparison to Industry Standards

• The failure of a lead Phase 3 drug, EBO-301, is a significant setback, common in the high-risk pharmaceutical development industry where success rates for drugs entering Phase 3 are typically around 50-60% across all therapeutic areas, and even lower for specific disease indications.
• The investor's call for liquidation or sale is a standard activist investor response when a company's primary value driver (a clinical asset) fails, and the remaining pipeline is early-stage with a long, uncertain path to commercialization. This strategy is often seen in small-cap biotech companies that lack diversified pipelines or significant cash reserves to weather such setbacks, unlike larger pharmaceutical companies (e.g., Pfizer, Merck) which can absorb individual drug failures due to their broad portfolios.
• The proposed return of $1.70+ per share suggests a valuation based primarily on cash and liquid assets, a common approach for companies facing a "going concern" issue or a lack of clear future value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for a cash return of $1.70 or more per share if liquidation occurs, or significant value erosion if the company pursues preclinical assets without success. The current shareholder base has already turned over significantly.
• Employees: Potential job losses if the company undergoes an orderly winddown or liquidation.
• Management/Board: Under pressure from a significant shareholder to change strategic direction; potential for directors to be voted out.

Next Steps

• AN2 Therapeutics' Board of Directors to consider BML's proposal for a sale, orderly winddown, liquidation, and capital return.
• Upcoming annual meeting of stockholders where BML plans to withhold votes for all three directors, serving as a referendum on shareholder preferences.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, BML Investment Partners, Schedule 13D, EBO-301, Phase 3 failure, drug development, biotech, liquidation, shareholder activism, capital return, pharmaceuticals, clinical trials, corporate governance